Concerns Emerge Over Potential Cancer Links to Drugs Like Ozempic

Published: Friday, August 8, 2025 at 7:00 pm

Concerns Emerge Over Potential Cancer Links to Weight Loss Drugs

The rising popularity of weight loss drugs, including semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro), has sparked scrutiny regarding their long-term health effects. While these medications have shown promise in aiding weight loss and managing type 2 diabetes, concerns are emerging about potential links to certain cancers.

Common side effects of these GLP-1 receptor agonists include gastrointestinal issues like nausea and vomiting. Additionally, rapid weight loss can lead to noticeable changes in appearance. More serious concerns involve potential connections to eye disease, reduced libido, and an increased risk of specific cancers.

The most significant cancer-related worry centers on thyroid cancer. Studies in rodents have shown a link between high doses of GLP-1 drugs and thyroid tumors, although this has not been definitively proven in humans. A large-scale study found a potential association between GLP-1 use and thyroid cancer, particularly in patients using the drug for over a year. As a precaution, these medications are not recommended for individuals with a personal or family history of thyroid cancer or specific genetic conditions that increase the risk of thyroid tumors.

Concerns have also been raised regarding pancreatic cancer, primarily due to early reports of pancreatitis. However, current studies have not confirmed a direct link between GLP-1 drugs and pancreatic cancer.

These drugs work by activating receptors in the pancreas to increase insulin release and reduce glucagon, helping to lower blood sugar levels. They also act on receptors in the brain, gut, and fat cells to reduce appetite, leading to weight loss. Tirzepatide, which acts on two receptors, has shown even greater weight loss effects. While tirzepatide has not been associated with increased cancer risk in clinical trials, it still carries the thyroid cancer warning.

It is important to note that obesity itself is a known risk factor for several cancers. GLP-1 drugs, by aiding weight loss, could indirectly reduce the risk of developing these conditions. Some studies have found lower rates of obesity-related cancers in people using GLP-1 medications. However, it remains unclear whether the reduced cancer risk is directly attributable to the drug or the weight loss itself.

BNN's Perspective: The available evidence suggests that the overall cancer risk associated with GLP-1 drugs is low. However, the potential for increased thyroid cancer risk warrants caution, especially for individuals with pre-existing risk factors. Further research is crucial to fully understand the long-term effects of these medications and to provide clear guidance for patients and healthcare providers.

Keywords: weight loss drugs, Ozempic, Wegovy, Mounjaro, semaglutide, tirzepatide, GLP-1 receptor agonists, thyroid cancer, pancreatic cancer, cancer risk, obesity, side effects, diabetes, insulin, glucagon

Full Story